Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06217393
Other study ID # ITOP-322-0216
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date February 28, 2024
Est. completion date February 28, 2025

Study information

Verified date April 2024
Source Abbott
Contact Suntje Sander
Phone '+49 (0) 511 6750 3254
Email suntje.sander@abbott.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: - assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar effect on gastrointestinal symptoms caused by gastric dysmotility and delayed gastric emptying, like bloating sensation, early satiety, postprandial fullness, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting in functional (non-ulcer) dyspepsia or chronic gastritis, as Itopride Hydrochloride 50 mg film coated tablets administered thrice a day. - investigate assessment of the treatment provided to each participant. - monitor safety and tolerability of Itopride Hydrochloride 150 mg extended release tablets, taken once daily before one of the main meals (preferably same meal throughout the treatment) and Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals.


Description:

This is a muti-national study, in subjects with functional dyspepsia. The study will screen approximately 700 subjects and include 564 subjects (282 subjects in both arms Test and Active control arm) and the treatment will be given as follows. - Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before any of the main meals (preferably same meal throughout the treatment) OR - Active Control group - Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals Total study participation will include screening for two weeks, treatment duration of eight weeks and follow-up for one week after the end of treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 564
Est. completion date February 28, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Adult male and/or non-pregnant non-lactating female subjects aged above 18 years. 2. Subjects provided written informed consent and are willing to participate in the study. 3. Subjects with functional (non-ulcer) dyspepsia according to Rome IV criteria including postprandial distress syndrome (PDS) and with or without EPS (epigastric pain syndrome) with one or more of the following: - bothersome postprandial fullness, - bothersome early satiation - bothersome epigastric pain, - bothersome epigastric burning for at least 12 weeks in the preceding 6 months 4. No evidence of organic, systemic, metabolic or structural disease likely to explain symptoms - Subjects who have to undergone physical examination and lab tests (including white-cell and red-cell counts, measurement of fasting blood sugar and liver-function tests), abdominal ultrasonography, and upper GI endoscopy* in order to rule out structural cause for symptoms of FD. *history of upper GI endoscopy within 6 months prior to enrolment or at screening. 5. Baseline severity of at least moderate symptoms on LDQ (total score = 9) at screening. 6. H. pylori negative documented test report within 3 months prior to enrolment or during screening. Exclusion Criteria: 1. Known hypersensitivity to Itopride or any component of the formulation and to any other related drug. 2. Subject with history or presence of clinically relevant evidence of cardiovascular, neurological, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/ connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant disease as revealed by medical history requiring treatment which at investigator's discretion might interfere with the study. 3. Subjects who cannot be treated with Itopride in line with the prescribing information. 4. Subjects scheduled for surgery during the study. 5. Subjects with a history of difficulty in swallowing. 6. Subject requiring concomitant treatment with anticholinergic drugs, drugs with narrow therapeutic index, sustained release or enteric-coated formulations. 7. Subjects taking Acid release inhibitors (e.g. histamine-2-receptor [H2]- antagonists, proton pump inhibitors [PPI], or potassium-competitive acid blockers), antacids (e.g. aluminium- or magnesium hydroxide, sodium bicarbonate), gastric mucosa protectors (e.g. sucralfate, rebamipide). 8. Subject with history of unusual bleeding and family history for bleeding disorders. 9. Subjects with only reflux-related symptoms or who have predominantly reflux-related symptoms. 10. Subjects with esophagitis, Barrett's esophagus, erosions or peptic ulcer disease within one year prior to the study or Zollinger-Ellison Syndrome. 11. Dyspepsia that is exclusively relieved by defecation or associated with a change in stool frequency or stool form to exclude IBS. 12. Clinically significant ECG abnormalities. 13. Subjects treated with Itopride or any other gastroprokinetic within 4 weeks prior to screening. 14. Subjects who took non-steroidal anti-inflammatory drugs for more than 2 weeks prior to screening 15. Subjects with refractory FD1 (defined as FD presenting symptoms continuing for at least 6 months, unresponsive to at least two medical treatments such as PPIs, prokinetics, or H. pylori eradication) as per investigator's discretion 16. History of or known inflammatory bowel disease (IBD) or coeliac disease. 17. History of or known severe hepatic, renal, pancreatic, cardiac, metabolic, hematological or malignant disease or trimethylaminuria. 18. Subjects with changed smoking status within the last three months. 19. History of or known GI malignancy or ulcers associated to malignancy or any alarm features for GI malignancy, e.g. GI bleeding. 20. Subjects who do not meet the criteria stated in concomitant medication section. 21. Subjects with history of severe depression, anxiety or other psychological disorders. 22. Females with child-bearing potential must agree to use an acceptable method of contraception during the study. 23. Subjects in whom an increase in gastrointestinal motility could be harmful, e.g., (history of) gastrointestinal hemorrhage, mechanical obstruction or perforation. 24. Specific food intolerance which is relieved by diet modifications (e.g. lactose intolerance, celiac disease). 25. Subjects with confirmed IBS as per Rome IV criteria. 26. Current alcohol or drug abuse. 27. History of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings or vasectomies. 28. Hepatic cirrhosis or abnormal liver laboratory findings (defined as >3xULN of ALT or AST). 29. Subjects under hemodialysis therapy or having advanced chronic kidney disease (defined as eGFR <60 mL/min). 30. History of or known congestive heart failure NYHA class III and IV, or any other uncontrolled chronic diseases, such as: uncontrolled hypertension (systolic/diastolic blood pressure =160/100 mmHg); uncontrolled diabetes (HbA1c >8%). 31. Subjects currently being known to be afflicted by serious infection(s), or any known severe illness(es) which are judged by the investigator could interfere with subjects' safety and/or study evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Itopride Hydrochloride 150 mg extended release tablets
The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Itopride Hydrochloride 50 mg film coated tablets
The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals

Locations

Country Name City State
Armenia "Grigor Narekatsi" MC, CJSC Yerevan
Armenia "Hera Med" LLC ("Medicus" Medical Center) Yerevan
Armenia "Institute of Surgery Mickaelyan" CJSC Yerevan
Armenia Polyclinic N 12 Health State, CJSC Yerevan
Malaysia Hospital Sultanah Bahiyah Alor Setar
Malaysia Queen Elizabeth Hospital Kota Kinabalu
Malaysia Pantai Hospital Kuala Lumpur Kuala Lumpur
Malaysia UMMC Petaling Jaya

Sponsors (1)

Lead Sponsor Collaborator
Abbott

Countries where clinical trial is conducted

Armenia,  Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment acceptance by subjects using 5-point Likert scale at the end of the treatment; (1. Not at all satisfied, 2. Slightly satisfied, 3. Neutral, 4. Very satisfied, 5. Extremely satisfied.) Treatment acceptance and ease of use assessed by subjects using 5-point Likert scale 8 weeks
Other To evaluate safety and tolerability in both treatment arms To evaluate the safety and tolerability of the two treatments by assessing the following safety endpoints: Treatment emergent adverse events (TEAEs) as detected by physical examination, laboratory assessments and vital signs. For each unique treatment, treatment emergent AEs will be summarized per primary standard of care, per Highest Level Term by primary Standard of care and per preferred term by highest level term and primary standard of care. 8 weeks
Primary To assess the comparable efficacy of Itopride Hydrochloride 150 mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 8 weeks' treatment Change in the overall severity of functional dyspepsia between baseline and week 8, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score 8 weeks
Secondary To assess the comparable efficacy of Itopride Hydrochloride 150mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 4 weeks treatment. Change in the overall severity of functional dyspepsia between baseline and week 4, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score 4 weeks
Secondary To assess quality of life for the two treatment arms using Disease Specific Quality of Life (Short Form - Nepean Dyspepsia Index SF-NDI) at baseline and end of treatment Disease Specific Quality of Life (Nepean Dyspepsia Index NDI) assessed at baseline and week 8 8 weeks
Secondary Assess the symptomatology (sensation of bloating, early satiety, abdominal pain or discomfort, epigastric pain, epigastric burning, anorexia, heartburn, nausea and vomiting) of the disease in both treatment arms after 4 and 8 weeks of treatment. Change from baseline of NRS 11 score for symptoms (sensation of bloating, early satiety, postprandial fullness, upper abdominal pain or discomfort (epigastric pain, epigastric burning), anorexia (loss of appetite), heartburn, nausea and vomiting) after 4 and 8 weeks of treatment 8 weeks
Secondary Change in the overall severity of functional dyspepsia between baseline and week 4, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score (range 0-40), where 0 is symptom free and 40 is severe dyspepsia Responder analysis for adequate/satisfactory relief as assessed by LDQ and/or NRS 11 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04464369 - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial Phase 4
Completed NCT01671670 - Acupuncture for Patients With Function Dyspepsia Phase 2/Phase 3
Completed NCT00987805 - Efficacy of Banhasasim-tang on Functional Dyspepsia Phase 4
Completed NCT00693407 - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation N/A
Completed NCT00761358 - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Phase 3
Recruiting NCT01240096 - Mirtazapine Versus Placebo in Functional Dyspepsia Phase 4
Recruiting NCT04540549 - Effects of Exercise on Functional Dyspepsia Based on Rome IV N/A
Recruiting NCT03652571 - Nortriptyline for the Treatment of Functional Dyspepsia Phase 3
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Recruiting NCT03825692 - International Clinical Study of Zhizhu Kuanzhong Capsule Phase 4
Not yet recruiting NCT04548011 - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia N/A
Terminated NCT02567578 - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia Phase 2
Completed NCT03007433 - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00404534 - Helicobacter Eradication Relief of Dyspeptic Symptoms Phase 3
Completed NCT03043625 - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia N/A
Completed NCT03225248 - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia Phase 3
Recruiting NCT05587127 - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia N/A
Recruiting NCT01021475 - Does Visceral Manipulation Works in Treating Functional Dyspepsia? Phase 1